Physician profile
Efim Weinman
NPI 1083676506
$799.31
in general payments reported to CMS, 2019-2025
14 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $433 · 2020: $196 · 2021: $21.14 · 2022: $149.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., INC. | $178.17 | 2019-2022 | |
| Lundbeck LLC | $138.78 | 2019-2022 | |
| Janssen Pharmaceuticals, INC | $90.79 | 2019-2020 | |
| Otsuka America Pharmaceutical, INC. | $80.50 | 2019-2020 | |
| Allergan, INC. | $63.35 | 2019 | |
| Vanda Pharmaceuticals INC. | $56.91 | 2019-2020 | |
| Bausch Health US, LLC | $34.54 | 2019 | |
| Abbvie INC. | $32.54 | 2022 | |
| Neurocrine Biosciences, INC. | $24.65 | 2022 | |
| Ironshore Pharmaceuticals INC. | $24.63 | 2019 | |
| Supernus Pharmaceuticals, INC. | $22.78 | 2022 | |
| Almatica Pharma LLC | $21.58 | 2022 | |
| Shire North American Group INC | $16.31 | 2019 | |
| Teva Pharmaceuticals USA, INC. | $13.78 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Efim Weinman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.